Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.

Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Abstract Text:

Brendan J Barrett,Richard W Katzberg,Henrik S Thomsen,Nan Chen,Dushyant Sahani,Gilles Soulez,Jay P Heiken,Luigi Lepanto,Zhou-Hui Ni,Rendon Nelson,Brendan J Barrett,Richard W Katzberg,Henrik S Thomsen,Nan Chen,Dushyant Sahani,Gilles Soulez,Jay P Heiken,Luigi Lepanto,Zhao-hui Ni,Zhou-Hui Ni,Rendon Nelson,

BACKGROUND: Based on a single clinical trial, it has been suggested that the contrast agent iodixanol, which is isotonic to human plasma, may be less nephrotoxic than other nonionic contrast agents in renally impaired patients after intra-arterial injection. We compared the effects on renal function of iopamidol-370 injection (796 mOsm/kg) and iodixanol-320 (290 mOsm/kg) in patients with chronic kidney disease undergoing contrast-enhanced multidetector computed tomography (CE-MDCT) examinations using a multicenter, double-blind, randomized, parallel-group design. METHODS: A total of 166 patients with stable moderate-to-severe chronic kidney disease (screening and baseline serum creatinine, SCr, > or =1.5 mg/dL and/or creatinine clearance, CrCl, < or =60 mL/min) who were undergoing CE-MDCT of the liver or peripheral arteries were randomized to receive equi-iodine IV doses (40 gI) of either iopamidol-370 (370 mgI/mL) or iodixanol-320 (320 mgI/mL) at 4 mL/s. SCr and CrCl were obtained at screening, baseline, and at 48-72 +/- 6 hours after dose (mean, 57.4 hours). Contrast-induced nephropathy (CIN) was defined as an absolute increase > or =0.5 mg/dL (44.2 micromol/L) and/or a relative increase in SCr > or =25% from baseline. RESULTS: A total of 153 patients were included in the final analysis (13 patients excluded because of lack of follow-up, hemodialysis to remove contrast, average daily CrCl variation >1% at screening). The 2 study groups were comparable with regard to age, gender distribution, the presence of diabetes, concomitant medications, hydration, and contrast dose. Mean predose SCr was 1.6 +/- 0.4 mg/dL in both groups (P = 0.9). An absolute increase > or =0.5 mg/dL (44.2 micromol/L) in SCr was observed in none of the patients receiving iopamidol-370 and in 2.6% (2/76) of patients receiving iodixanol-320 (95% confidence interval -6.2, 1.0, P = 0.2). A relative increase > or =25% in SCr occurred in 4% (3/77) of patients receiving iopamidol-370 and in 4% (3/76) of the patients receiving iodixanol-320 (95% confidence interval -6.2, 6.1, P = 1.0). CONCLUSION: The rate of CIN was similarly low in risk patients after intravenous administration of iopamidol-370 or iodixanol-320 for CE-MDCT.

Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Publishing Authors By Initials

BJ Barrett,RW Katzberg,HS Thomsen,N Chen,D Sahani,G Soulez,JP Heiken,L Lepanto,ZH Ni,R Nelson,BJ Barrett,RW Katzberg,HS Thomsen,N Chen,D Sahani,G Soulez,JP Heiken,L Lepanto,ZH Ni,ZH Ni,R Nelson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Investigative radiology

VOLUME: 41

Page Numbers: 815-21

Journal Abbreviation:

ISSN: 0020-9996

DAY: 12

MONTH: Nov

YEAR: 2006

Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 45377

Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.

AFFILIATION: Patient Research Centre, Health Science Center, St. John's, NL, Canada. bbarrett@mum.ca

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Invest Radiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol Related Publications

• Au(I)-catalyzed annulation of enantioenriched allenes in the enantioselective total synthesis of (-)-rhazinilam.
• CARBON DIOXIDE AS AN ATTRACTANT FOR CULICOIDES.
• CDK/GSK-3 inhibitors as a new approach for the treatment of proliferative renal diseases.
• CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney.
• Catalytic asymmetric assembly of stereodefined propionate units: an enantioselective total synthesis of (-)-pironetin.
• Chronic binge ethanol consumption accelerates progression of simian immunodeficiency virus disease.
• Collapsing glomerulopathy.
• Common bacterial infections of the skin.
• Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol.
• Determining global population distribution: methods, applications and data.
• Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling.
• EPR and ENDOR study of radiation-induced radical formation in purines: hypoxanthine hydrochloride monohydrate crystals X-irradiated at 10 K.
• EPR and ENDOR study of radiation-induced radical formation in purines: sodium inosine crystals X-irradiated at 10 K.
• Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis.
• Electron transfer in amino acid.nucleic acid base complexes: EPR, ENDOR, and DFT study of X-irradiated N-formylglycine.cytosine complex crystals.
• Ethical challenges in neonatal research: Summary report of the ethics group of the newborn drug development initiative.
• Feasibility of dynamic susceptibility contrast perfusion MR imaging at 3T using a standard quadrature head coil and eight-channel phased-array coil with and without SENSE reconstruction.
• Genome-wide analysis reveals new roles for the activation domains of the Saccharomyces cerevisiae heat shock transcription factor (Hsf1) during the transient heat shock response.
• HIV incidence among injection drug users in Baltimore, Maryland (1988-2004).
• Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation.
• Identifying and overcoming the barriers to high-quality palliative care in the intensive care unit.
• Maternal microchimerism in healthy adults in lymphocytes, monocyte/macrophages and NK cells.
• Mononuclear infiltrates in osteosarcoma and chemokine receptor expression.
• Neural bases and development of face recognition in autism.
• Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
• Photoperiod differentially affects immune function and reproduction in collared lemmings (Dicrostonyx groenlandicus).
• Pregnancy and obesity: a review and agenda for future research.
• Social and photoperiod effects on reproduction in five species of Peromyscus.
• Surface plasmon resonance-enabled mass spectrometry arrays.
• [Sleeping position to prevent sudden infant death syndrome in Latin-american and Caribbean hospitals]